This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES Asia: Oligonucleotide & Peptide Therapeutics
26-28 Feb, 2025
Westin Miyako KyotoKyoto, Japan

Zdravka Medarova, PhD
Co-Founder and Chief Scientific Officer at TransCode Therapeutics
Speaker

Profile

Zdravka Medarova, PhD has served as Scientific Co-Founder and a member of the advisory board of TransCode since January 2016 and is TransCode's Chief Scientific Officer. Dr. Medarova is also on the Faculty of Harvard Medical School. She has served as an Associate Professor of Radiology at Harvard Medical School since April 2016. Dr. Medarova is a geneticist/cancer biologist by training. Dr. Medarova is internationally recognized for her work on non-coding RNA for cancer therapy. She is one of the first to describe the design and application of nanoparticles as carriers of siRNA to tumors. Since then, her research has focused on developing nanotechnology and imaging tools to better understand cancer initiation and progression and applying this knowledge to design clinically relevant therapeutic and diagnostic agents against cancer.

Agenda Sessions

  • Phase 1 Clinical Testing of a First-in-Class ASO Therapeutic against Metastatic Cancer

    9:15am